case_images: PMC10898915_01
case_images: Micrograph of the unstained tumour. Micrograph (40x) of the tumour excised during surgery; the brown colouration of some cells reveals the presence of melanin, suggesting melanoma.
case_images: can-17-1610fig1.jpg
case_images: PMC10898915_01_can-17-1610fig1.jpg
case_images: figure1
case_images: The postoperative histopathological result revealed pigmented and ulcerated anorectal invasive melanoma, with the presence of pleomorphic giant cells (Figures 1 and 2).
case_images: Micrograph of the tumour stained with haematoxylin-eosin. Micrograph (40x) of the tumour excised during surgery with haematoxylin-eosin stain. The anorectal mucosa is infiltrated by malignant epithelioid neoplastic cells with prominent nucleoli and melanin.
case_images: can-17-1610fig2.jpg
case_images: PMC10898915_01_can-17-1610fig2.jpg
case_images: figure2
case_images: The postoperative histopathological result revealed pigmented and ulcerated anorectal invasive melanoma, with the presence of pleomorphic giant cells (Figures 1 and 2).
case_images: RT planning target volume. Planning target volume of the postoperative patient is outlined in orange. The large image is along the transverse plane, whereas the top and bottom images are of the sagittal and coronal planes, respectively.
case_images: can-17-1610fig3.jpg
case_images: PMC10898915_01_can-17-1610fig3.jpg
case_images: figure3
case_images: The patient was evaluated by medical oncology which referred her to the radiotherapy service for a dose of 50 Gy in 25 3D sessions to the pelvic region using a CLINAC 2300 model IX linear accelerator (Varian Medical Systems, Inc., USA), which was adequately tolerated (Figures 3 and 4).
case_images: Radiation planning dose. 3D pelvic cavity RT planning in the postoperative patient at a dose of 50 Gy in 25 fractions. This transverse image presents the dose distribution to the pelvic cavity.
case_images: can-17-1610fig4.jpg
case_images: PMC10898915_01_can-17-1610fig4.jpg
case_images: figure4
case_images: The patient was evaluated by medical oncology which referred her to the radiotherapy service for a dose of 50 Gy in 25 3D sessions to the pelvic region using a CLINAC 2300 model IX linear accelerator (Varian Medical Systems, Inc., USA), which was adequately tolerated (Figures 3 and 4).